Adial Pharmaceuticals Inc (NASDAQ:ADIL) has been awarded a new U.S. patent expanding the coverage of the combination of the company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and drug dependencies, such as opioid use disorder (OUD), with the company’s lead investigational new drug product AD04. The Patent Notice of Allowance from the United States Patent and Trademark Office expands patents covering Adial’s molecular genetic approach to diagnosing and potentially treating alcohol and drug depend…
